The patents, which the company says are its 17th and 18th in the joint health arena, apply constituents in its FlexPro MD and FlexPro ES formulas. The patents relate to the company’s hyaluronic acid and astaxanthin ingredients.
One patent was issued for and ingredient called Flexuron Plus, Valensa’s proprietary, non-animal derived, and highly-bioactive formula that features medium-chain hyaluronic acid (which has a lower molecular weight than traditional hyaluronic acid), when used in combination with the antioxidant astaxanthin.
The second patent was granted to Valensa for their Zanthin brand astaxanthin in combination with the medium-chain hyaluronic acid and also teamed with phospholipids. Using the surfactant phospholipids boosts the formula’s beneficial effects on knee joint discomfort, the company claims.
“We’re proud that this patent family secures our discovery in Flexuron Plus whose ingredients are central to the effectiveness of our FlexPro MD® commercial joint care product,” said Umasudhan C.P., CEO of Valensa.